DNLI News and Press, Denali Therapeutics Inc. From 08/11/22

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Growth Fund declined 18.69% (Institutional Shares) during the quarter ended June 30, 2022. We think that the co...

Denali Therapeutics press release ( NASDAQ: DNLI ): Q2 GAAP EPS of -$0.48 beats by $0.04 . Revenue of $52.48M (+128.8% Y/Y) beats by $7.82M . For further details see: Denali Therapeutics GAAP EPS of -$0.48 beats by $0.04, revenue of $52.48M beats by $7.82...

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial r...

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the development of novel therapies to treat central nervous sys...

Berenberg has started Denali Therapeutics (NASDAQ:DNLI) with a buy rating saying that the central nervous system ("CNS")-focused company has technology making it possible to get drugs directly into the brain. The firm has a $39 price target (~43% upside based on Wednesday's close). Analyst Ca...

Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It includes many rare neurological disease disorders like Alzheimer&#...

Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still projected to continue to grow over the next years to come...

BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s disease Phase 2b LUMA to enroll approximately 640 participants with early-stage Parkinson’s disease; most advanced clinica...

Denali Therapeutics press release (NASDAQ:DNLI): Q1 GAAP EPS of -$0.53 misses by $0.03. Revenue of $42.14M (+432.1% Y/Y) beats by $8.82M. For further details see: Denali Therapeutics GAAP EPS of -$0.53 misses by $0.03, revenue of $42.14M beats by $8.82M

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial re...